StockNews.AISignal intelligence
Butterfly Network, Inc. · NYSE · Healthcare
Browse public BFLY signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Butterfly reported Q2 revenue of $32.51M, rising 39% year over year, and an adjusted loss of $0.01 per share, better than the $0.06 consensus loss. The beat was driven by Butterfly Embedded partnerships, including a Midjourney co-development tie-up, and left the company with $124.7M in cash. Management raised full-year guidance and issued a stronger Q3 target, supporting a near-term rally.
View signal analysisButterfly Network announced Brazil-wide availability of its handheld ultrasound devices on July 2, signaling a near-term market expansion and potential revenue uplift. The stock jumped 7.2% after the news, aided by generally positive sentiment from Jim Cramer. This catalyst could drive short-term gains for BFLY, contingent on ongoing adoption and broader market demand.
View signal analysisButterfly Network (BFLY) confirms details of its co-development with Midjourney for a full-body tomographic imaging platform. The prototype uses 40 Ultrasound-on-Chip modules, with plans for more, tied to up to $74 million in payments over five years. The arrangement could broaden Butterfly Embedded opportunities and provide a material long-term revenue driver if the platform achieves market traction.
View signal analysisButterfly Network has received U.S. regulatory approval for its AI-powered ultrasound tool that estimates gestational age. This breakthrough is expected to expand maternal healthcare access in underserved regions, potentially driving growth and increased market presence for Butterfly Network.
View signal analysis